FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126572359> ?p ?o ?g. }

• W2126572359 endingPage "e15298" @default.
• W2126572359 startingPage "e15298" @default.
• W2126572359 abstract "Background Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson's disease. The purpose of the present study was to investigate the efficacy of amantadine in Parkinson's disease patients suffering from dyskinesias. Methods In this multi-center, double-blind, randomized, placebo-controlled, cross-over trial, 36 patients with Parkinson's disease and dyskinesias were randomized, and 62 interventions, which included amantadine (300 mg /day) or placebo treatment for 27 days, were analyzed. At 15 days after washout, the treatments were crossed over. The primary outcome measure was the changes in the Rush Dyskinesia Rating Scale (RDRS) during each treatment period. The secondary outcome measures were changes in the Unified Parkinson's Disease Rating Scale part IVa (UPDRS-IVa, dyskinesias), part IVb (motor fluctuations), and part III (motor function). Results RDRS improved in 64% and 16% of patients treated with amantadine or placebo, respectively, with significant differences between treatments. The adjusted odds-ratio for improvement by amantadine was 6.7 (95% confidence interval, 1.4 to 31.5). UPDRS-IVa was improved to a significantly greater degree in amantadine-treated patients [mean (SD) of 1.83 (1.56)] compared with placebo-treated patients [0.03 (1.51)]. However, there were no significant effects on UPDRS-IVb or III scores. Conclusions Results from the present study demonstrated that amantadine exhibited efficacious effects against dyskinesias in 60–70% of patients. Trial Registration UMIN Clinical Trial Registry UMIN000000780" @default.
• W2126572359 created "2016-06-24" @default.
• W2126572359 creator A5027866038 @default.
• W2126572359 creator A5029368734 @default.
• W2126572359 creator A5035583339 @default.
• W2126572359 creator A5038674875 @default.
• W2126572359 creator A5042691162 @default.
• W2126572359 creator A5047187786 @default.
• W2126572359 creator A5049043438 @default.
• W2126572359 creator A5049103759 @default.
• W2126572359 date "2010-12-31" @default.
• W2126572359 modified "2023-10-18" @default.
• W2126572359 title "Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial" @default.
• W2126572359 cites W1945424073 @default.
• W2126572359 cites W1976645888 @default.
• W2126572359 cites W1998212419 @default.
• W2126572359 cites W2007037518 @default.
• W2126572359 cites W2039376183 @default.
• W2126572359 cites W2043227557 @default.
• W2126572359 cites W2052510409 @default.
• W2126572359 cites W2053473574 @default.
• W2126572359 cites W2068390799 @default.
• W2126572359 cites W2078208735 @default.
• W2126572359 cites W2093755310 @default.
• W2126572359 cites W2095868750 @default.
• W2126572359 cites W2097863680 @default.
• W2126572359 cites W2108476536 @default.
• W2126572359 cites W2117800002 @default.
• W2126572359 cites W2118015000 @default.
• W2126572359 cites W2136541816 @default.
• W2126572359 cites W2137849205 @default.
• W2126572359 cites W2141289992 @default.
• W2126572359 cites W2145993448 @default.
• W2126572359 cites W2151320291 @default.
• W2126572359 cites W2152069319 @default.
• W2126572359 cites W2152240392 @default.
• W2126572359 doi "https://doi.org/10.1371/journal.pone.0015298" @default.
• W2126572359 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3013111" @default.
• W2126572359 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21217832" @default.
• W2126572359 hasPublicationYear "2010" @default.
• W2126572359 type Work @default.
• W2126572359 sameAs 2126572359 @default.
• W2126572359 citedByCount "116" @default.
• W2126572359 countsByYear W21265723592012 @default.
• W2126572359 countsByYear W21265723592013 @default.
• W2126572359 countsByYear W21265723592014 @default.
• W2126572359 countsByYear W21265723592015 @default.
• W2126572359 countsByYear W21265723592016 @default.
• W2126572359 countsByYear W21265723592017 @default.
• W2126572359 countsByYear W21265723592018 @default.
• W2126572359 countsByYear W21265723592019 @default.
• W2126572359 countsByYear W21265723592020 @default.
• W2126572359 countsByYear W21265723592021 @default.
• W2126572359 countsByYear W21265723592022 @default.
• W2126572359 countsByYear W21265723592023 @default.
• W2126572359 crossrefType "journal-article" @default.
• W2126572359 hasAuthorship W2126572359A5027866038 @default.
• W2126572359 hasAuthorship W2126572359A5029368734 @default.
• W2126572359 hasAuthorship W2126572359A5035583339 @default.
• W2126572359 hasAuthorship W2126572359A5038674875 @default.
• W2126572359 hasAuthorship W2126572359A5042691162 @default.
• W2126572359 hasAuthorship W2126572359A5047187786 @default.
• W2126572359 hasAuthorship W2126572359A5049043438 @default.
• W2126572359 hasAuthorship W2126572359A5049103759 @default.
• W2126572359 hasBestOaLocation W21265723591 @default.
• W2126572359 hasConcept C126322002 @default.
• W2126572359 hasConcept C142724271 @default.
• W2126572359 hasConcept C156957248 @default.
• W2126572359 hasConcept C168563851 @default.
• W2126572359 hasConcept C204787440 @default.
• W2126572359 hasConcept C27081682 @default.
• W2126572359 hasConcept C2776525014 @default.
• W2126572359 hasConcept C2777374534 @default.
• W2126572359 hasConcept C2779134260 @default.
• W2126572359 hasConcept C2779734285 @default.
• W2126572359 hasConcept C2780304432 @default.
• W2126572359 hasConcept C2780405171 @default.
• W2126572359 hasConcept C42219234 @default.
• W2126572359 hasConcept C535046627 @default.
• W2126572359 hasConcept C71924100 @default.
• W2126572359 hasConcept C98274493 @default.
• W2126572359 hasConceptScore W2126572359C126322002 @default.
• W2126572359 hasConceptScore W2126572359C142724271 @default.
• W2126572359 hasConceptScore W2126572359C156957248 @default.
• W2126572359 hasConceptScore W2126572359C168563851 @default.
• W2126572359 hasConceptScore W2126572359C204787440 @default.
• W2126572359 hasConceptScore W2126572359C27081682 @default.
• W2126572359 hasConceptScore W2126572359C2776525014 @default.
• W2126572359 hasConceptScore W2126572359C2777374534 @default.
• W2126572359 hasConceptScore W2126572359C2779134260 @default.
• W2126572359 hasConceptScore W2126572359C2779734285 @default.
• W2126572359 hasConceptScore W2126572359C2780304432 @default.
• W2126572359 hasConceptScore W2126572359C2780405171 @default.
• W2126572359 hasConceptScore W2126572359C42219234 @default.
• W2126572359 hasConceptScore W2126572359C535046627 @default.
• W2126572359 hasConceptScore W2126572359C71924100 @default.
• W2126572359 hasConceptScore W2126572359C98274493 @default.
• W2126572359 hasIssue "12" @default.

• next